Dapitant, formerly known as RPR100893, is potent and selective NK1 receptor antagonist both in vitro and in vivo, and exhibits high affinity for guinea pig and human NK1 receptor . Dapitant was developed as a potential drug for the acute treatment of migraine. However, in clinical trials, it was not effective. References: Diener HC; RPR100893 Study Group. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia. 2003 Apr;23(3):183-5. PubMed PMID: 12662184.

纯度：≥98%

CAS：153438-49-4